China Boosts Health System Reforms With Expanded National Drug Reimbursement List
This article was originally published in PharmAsia News
Executive Summary
BEIJING - In the government's latest move to expand coverage under sweeping health system reforms that are in the works China-wide, the Ministry of Human Resources and Social Security has added hundreds of new medicines to the latest edition of the national drug reimbursement catalog
You may also be interested in...
Lost In Reimbursement? Innovative Drugs Encounter Lengthy Delays In China – IMS Study
A market access study conducted by IMS and RDPAC sheds lights on regulatory and reimbursement challenges facing MNCs in China.
Lost In Reimbursement? Innovative Drugs Encounter Lengthy Delays In China – IMS Study
A market access study conducted by IMS and RDPAC sheds lights on regulatory and reimbursement challenges facing MNCs in China.
China Sets New Rule For Drug Price Differentiation
China’s National Development and Reform Commission Dec. 2 releases new regulation on drug price differentiation intended to close loopholes.